Hepatitis C treatment: The data flood goes on - An update from the liver meeting 2014

Gastroenterology

Volumn 148, Issue 3, 2015, Pages 468-479

  Pawlotsky, Jean Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR;

DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; MIXED INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT FAILURE; DRUG COMBINATION; ORGANIZATION;

ANTIVIRAL AGENTS; CONGRESSES AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS;

EID: 84923875654     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.01.002     Document Type: Editorial

References (20)

1. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
2. E.J. Gane, C.A. Stedman, and R.H. Hyland Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
3. I.M. Jacobson, S.C. Gordon, and K.V. Kowdley Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
4. E. Lawitz, M.S. Sulkowski, and R. Ghalib Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
5. M.S. Sulkowski, D.F. Gardiner, and M. Rodriguez-Torres Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
6. F. Poordad, C. Hezode, and R. Trinh ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
7. I. Ruiz, C. Feray, and J.M. Pawlotsky Decompensated hepatitis C virus-related cirrhosis delisted from liver transplantation after successful sofosbuvir-based treatment Liver Transpl 2014 Nov 25 [Epub ahead of print]
8. P.Y. Kwo, P.S. Mantry, and E. Coakley An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med 371 2014 2375 2382
9. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2014 J Hepatol 61 2014 373 395
10. J.M. Pawlotsky New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development Semin Liver Dis 34 2014 22 29
11. K.V. Kowdley, S.C. Gordon, and K.R. Reddy Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
12. A. Kohli, A. Osinusi, and Z. Sims Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study Lancet 2015 Jan 12 [Epub ahead of print]
13. N. Afdhal, K.R. Reddy, and D.R. Nelson Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
14. N. Afdhal, S. Zeuzem, and P. Kwo Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
15. E. Lawitz, A. Mangia, and D. Wyles Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
16. S. Chevaliez, C. Rodriguez, and J.M. Pawlotsky New virologic tools for management of chronic hepatitis B and C Gastroenterology 142 2012 1303 1313 e1
17. R.J. Barnard, J.A. Howe, and R.A. Ogert Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
18. J.C. Sullivan, S. De Meyer, and D.J. Bartels Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
19. E. Lawitz, E. Gane, and B. Pearlman Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2014 Nov 11 [Epub ahead of print]
20. M. Sulkowski, C. Hezode, and J. Gerstoft Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2014 Nov 11 [Epub ahead of print]